Weight-Management Outlook 2010

Countries covered: United States By 2015, the World Health Organization projects that there will be 2.3 billion overweight adults and 700 million obese adults around the world. The U.S. has the highest obesity rates worldwide. Rates of obesity in developing countries have tripled during the past two decades. Despite these glaring statistics, the global obesity market was valued at only $2 billion during 2008 due to a limited availability of therapeutic options. During the past two decades, prescription treatments for the obesity category have come under increased scrutiny by FDA, physicians, and patients. Radical heart-related side effects led to the market withdrawal of Fen-Phen in the 1990s. During 2009, safety concerns increased with FDA's response to reports of liver injury in patients taking GlaxoSmithKline's alli and Roche's Xenical, both containing the active ingredient orlistat. And in January, FDA notified physicians that Abbott Laboratories' Meridia may lead to an increased risk of heart attack and stroke in patients with a history of cardiovascular disease. In addition to safety concerns, companies have hesitated to develop weight-control drugs because of insufficient scientific knowledge and refusal of healthcare regulators to grant reimbursement for such products. Although the pharmaceutical industry has lead discovery for weight-management products in the past, biotechnology and biopharmaceutical companies are emerging as the new leaders in developing and bringing obesity products to market. These products are expected to be effective and safe, and are anticipated to assist with related conditions such as diabetes and blood pressure. Promising late-stage pipeline products include Arena Pharmaceuticals' lorcaserin, Vivus' Qnexa, and Orexigen Therapeutics' Contrave. IntraPace Inc.'s abiliti system is an investigational device designed to provide stimulation to the stomach when food or drink is detected to create an early feeling of fullness. Abiliti contains sensors intended to track consumption and physical activity data, which can be downloaded at a doctor's office and used to monitor a patient's progress toward weight-loss goals. Meanwhile, other companies are developing scientifically advanced electroencephalograph (EEG) equipment to help with obesity and related conditions. These brain-monitoring systems are considered lower-cost and space-saving alternatives to traditional MRI and CT equipment. In this report, readers can get insight into the product pipelines for weight management and obesity as well as the therapeutic areas related to these conditions, including diabetes, heart disease, and hypertension; review qualitative analysis of the most promising weight-control drugs and emerging discovery and development strategies; track potentially competitive products, identify those that have market-leading potential, and learn how these could affect your company's market share; understand the competitive landscape and future growth drivers shaping the weight-control market; uncover partnership opportunities within the weight-control market that could improve your company's product portfolio; learn how treatment of overweight and obesity will impact development in related therapeutic areas.

Additional Information

This special report contains analysis and charts examining the field of weight-management and related disease areas in the pharmaceutical and medical-device sectors. Primary disease areas covered:

1. Weight control
2. Diabetes
3. Hypertension
4. Heart disease

Prescription-drug pipelines for the disease areas above detail the following for each product:

• Each pipeline products’ chemical or substance composition, intended indication, class of drug, clinical status, region of development, and the product developer/intended marketer
• Pipeline status details preclinical development, Phase I, Phase II, Phase II/III, Phase III, and awaiting approval
• Region of development includes the United States, Europe, and Japan

A directory of prescription-drug and medical-device developers/marketers for the disease categories above includes the following for each company:

• Mailing address
• General phone, fax, e-mail, and Website
• Year established

More United States Prescription Drugs Reports

2012 Healthcare Business Market Research Handbook by Richard K. Miller & Associates
The 2012 Healthcare Business Market Research Handbook presents a comprehensive analysis of the $2.8 trillion U.S. healthcare marketplace with the most recent statistics and data ...

Brand Name Pharmaceutical Manufacturing in the US - Industry Market Research Report by IBISWorld
Brand Name Pharmaceutical Manufacturing in the US Prescription for growth With healthcare reform allowing more individuals to gain prescription coverage, brand-name pharmaceutical and medicine manufacturers will experience ...

Analysis of the United States Contract Manufacturing Outsourcing Market by Frost & Sullivan
Contract manufacturing outsourcing (CMO) companies provide independent manufacturing services for pharmaceutical and biotechnological markets. This study covers the U.S. commercial manufacturing and packaging of pharmaceutical ...

United States Pharmaceuticals and Healthcare Report Q2 2012 by Business Monitor International
BMI View: Economics and politics are increasingly exerting an influence on the US pharmaceuticalmarket. This is in stark contrast to the late 1990s and early ...

The US Pharmaceutical Market Outlook to 2016 - Evolving Opportunities in the Biologics Segment by AM Mindpower Solutions
EXECUTIVE SUMMARY The report titled “The US Pharmaceutical Market Outlook to 2015 – Evolving Opportunities in the Biologics Segment” provides a comprehensive analysis on the Pharmaceutical ...

See all reports like this >>

More United States Reports

e-Discovery Software Publishing in the US - Industry Market Research Report by IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...

D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country Report: The United States of America by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Country Report United States January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Coal - US - a snapshot (2010) by Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...

See all reports like this >>